Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexelizumab in acute ST-elevation myocardial infarction undergoing primary PCI
2004-000142-20Phase 3Terminated
- Sponsor
- Procter & Gamble
- Start
- Nov 2004
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Pexelizumab with Placebo (2 arms). Primary endpoint: All-cause mortality at Day 90. Started Nov 2004; status: terminated.
02
Drugs
pexelizumab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2004-000142-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000142-20.